Pancreatic Cancer: Why Is It Hard to Detect Early? Symptoms, Diagnosis, and New Treatment Advances

The pancreas is an organ located behind the stomach, stretching across the upper abdomen. It produces digestive enzymes and hormones that regulate blood sugar, including insulin. Pancreatic cancer mostly starts in the cells lining the pancreatic ducts. Because the pancreas lies deep in the abdominal cavity, early tumors cause almost no symptoms, and most cases are already at an advanced stage when diagnosed. This is why it is called the 'king of cancers.'

Although pancreatic cancer is very challenging to treat, recent improvements in chemotherapy regimens, precision medicine, and breakthroughs in RAS-targeted drugs are gradually changing the outlook for this cancer type. Understanding the risks and warning signs is still the best way to gain time.

Causes and Risk Factors

The exact causes of pancreatic cancer are not fully understood, but known risk factors include: smoking (the most important avoidable factor), long-term chronic pancreatitis, diabetes (especially newly diagnosed after age 50 with weight loss), obesity, and increasing age (most common over age 60).

Genetic factors also account for about 10%: people with multiple family members who had pancreatic cancer, or who carry gene mutations such as BRCA1/BRCA2, are at higher risk. These high-risk individuals can discuss with their doctor about regular monitoring with MRI or endoscopic ultrasound.

Common Symptoms and Warning Signs

Early symptoms of pancreatic cancer are very nonspecific: vague upper abdominal pain (sometimes radiating to the back), loss of appetite, indigestion, and weight loss. These are easily mistaken for stomach problems. These vague symptoms are the main reason for delayed diagnosis.

A more typical warning sign is painless jaundice — when the tumor is in the head of the pancreas, it can block the bile duct, causing yellowing of the skin and whites of the eyes, dark tea-colored urine, pale gray stools, and itchy skin. In addition, sudden worsening of previously well-controlled diabetes, or new-onset diabetes without a clear cause, warrants further examination of the pancreas.

Diagnosis and Staging Concepts

When pancreatic cancer is suspected, a CT scan is the main test to assess tumor location, size, and blood vessel involvement. MRI and endoscopic ultrasound (EUS) provide more details, and EUS can also directly take tissue samples with a needle for testing. The blood tumor marker CA19-9 is often used as an auxiliary reference and to track treatment response, but it cannot be used alone to confirm diagnosis.

Staging is closely linked to whether surgery is possible: resectable, borderline resectable (tumor close to major blood vessels), locally advanced (tumor encasing blood vessels), and metastatic (stage IV). Only about 20% of patients can have surgery immediately at diagnosis, so staging evaluation is crucial for treatment planning.

Overview of Treatment Options

Surgery (such as pancreaticoduodenectomy) is the only chance for a cure. After surgery, adjuvant chemotherapy is given to reduce recurrence. For borderline resectable patients, chemotherapy (sometimes with radiation) is usually given first to shrink the tumor, then surgery is reassessed.

Advanced pancreatic cancer is mainly treated with chemotherapy. Common combinations include FOLFIRINOX or gemcitabine plus nab-paclitaxel. In precision medicine: about 10% of patients have gene mutations such as BRCA and may consider maintenance therapy with PARP inhibitors. For KRAS mutations (present in over 90% of pancreatic cancers), RAS-targeted drugs have recently made breakthrough progress, bringing long-awaited hope for this cancer type.

Clinical Trials: Another Treatment Option

Pancreatic cancer is one of the most urgent areas for new drug development. RAS inhibitors, new chemotherapy combinations, immunotherapy combination strategies, and cancer vaccines are all being actively tested in clinical trials. For pancreatic cancer patients, clinical trials are often the best way to access breakthrough therapies.

The CancerLink platform can screen for pancreatic cancer clinical studies recruiting in Hong Kong based on cancer type, stage, and gene mutations. After successful matching and enrollment, study-related treatment costs are fully covered. It is recommended to have genetic testing as soon as possible after diagnosis and discuss the possibility of clinical trials with your doctor.

A pancreatic cancer diagnosis is indeed hard to accept, but please do not give up: chemotherapy regimens are improving, targeted drugs are making breakthroughs, and clinical trials are accelerating. Bring your genetic testing report and work with your oncology team to find the most proactive and suitable treatment path for you.